Page last updated: 2024-09-04

vatalanib and Neoplasms

vatalanib has been researched along with Neoplasms in 32 studies

Research

Studies (32)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's18 (56.25)29.6817
2010's13 (40.63)24.3611
2020's1 (3.13)2.80

Authors

AuthorsStudies
Acemoglu, F; Altmann, KH; Bold, G; Boss, E; Brüggen, J; Buchdunger, E; Cozens, R; Emmenegger, R; Ferrari, S; Frei, J; Furet, P; Hofmann, F; Lang, M; Lässer, L; Manley, PW; Martiny-Baron, G; Masso, E; Mestan, J; Rösel, J; Roth, R; Schlachter, C; Sills, M; Stover, D; Traxler, P; Vetterli, W; Wietfeld, B1
Aono, H; Ban, M; Honda, T; Inaba, T; Inoue, K; Kawashima, K; Okamoto, K; Sasabuchi, Y; Tajima, H; Takeno, Y; Yamamoto, M1
Aono, H; Ban, M; Honda, T; Inaba, T; Inoue, K; Kawashima, K; Okamoto, K; Sasabuchi, Y; Tajima, H; Takeno, Y; Tonouchi, A; Tsuboi, T; Yamamoto, M1
Brullo, C; Musumeci, F; Radi, M; Schenone, S1
Adjei, AA; Croghan, GA; Dy, GK; Glockner, J; Hanson, LJ; Molina, JR; Qi, Y; Roos, MM; Tan, AD; Zhu, M1
Adjei, AA; Lim, VS; Molina, J; Satele, D; Wang, F; Yin, J1
Berg, W; Freeman, B; Manno, P; Sharma, S; Symanowski, J; Turner, J; Vogelzang, N1
Antoniadis, H; Christofori, G; Crnic, I; Littlewood-Evans, A; Schomber, T; Strittmatter, K; Wood, J; Zumsteg, A1
Chiorean, EG; Hall, SD; Jones, DR; Malireddy, S; Schneider, B; Sloop, MI; Sweeney, CJ; Waddell, MJ; Younger, AE; Yu, M1
Beijnen, JH; Langenberg, MH; Lankheet, NA; Roodhart, JM; Rosing, H; van den Heuvel, IJ; Voest, EE; Witteveen, PO1
Buechert, M; Chen, BL; Drevs, J; Fuxius, S; Hennig, J; Laurent, D; Lebwohl, D; Medinger, M; Mross, K; Thomas, A; Unger, C1
Burris, H; Doss, H; Greco, FA; Hainsworth, J; Infante, J; Jones, S; Spigel, D; Thompson, D1
Böhm-Sturm, P; Diedenhofen, M; Hoehn, M; Jikeli, JF; Ullrich, RT; Unruh, M; Vollmar, S1
Tolcher, AW1
Burris, HA; Jones, SF; Spigel, DR; Thompson, DF; Yardley, DA1
Döme, B; Török, S1
Cserepes T, M; Döme, B; Rényi-Vámos, F; Török, S1
Rosen, LS1
Durrance, A; Erlich, R1
Shiotsu, Y1
Marmé, D1
Cavanaugh, SX; Hammond, LA; Thomas, CR1
Kiziltepe, T; Sasisekharan, R; Sengupta, S1
Doherty, M1
Haberey, M; Hess-Stumpp, H; Thierauch, KH1
Higginson, A; Horsfield, MA; Kay, A; Laurent, D; Lee, L; Masson, E; Morgan, B; Puccio-Pick, M; Steward, WP; Thomas, AL1
Soff, G; Zakarija, A1
Agarwala, SS; Tawbi, H1
Filov, VA; Gershanovich, ML; Imianitov, EN; Stukov, AN1
Denner, K; Gross, G; Gschwind, HP; Guenther, C; Jalava, T; Jost, LM; Laurent, D; Masson, E; Rottmann, A; Souppart, C; Waldmeier, F; Wang, Y1
Jacques, C; Laurent, D; Meinhardt, G; Scott, EN; Thomas, AL1
Armand, JP; Mir, O; Ropert, S1

Reviews

9 review(s) available for vatalanib and Neoplasms

ArticleYear
The evolution of phase I trials in cancer medicine: a critical review of the last decade.
    Chinese journal of cancer, 2011, Volume: 30, Issue:12

    Topics: Antineoplastic Agents; Clinical Trials, Phase I as Topic; Drug Delivery Systems; Gefitinib; Humans; Maximum Tolerated Dose; Molecular Targeted Therapy; Neoplasms; Phthalazines; Positron-Emission Tomography; Protein Kinase Inhibitors; Pyridines; Quinazolines

2011
[Possibilities for inhibiting tumor-induced angiogenesis: results with multi-target tyrosine kinase inhibitors].
    Magyar onkologia, 2012, Volume: 56, Issue:1

    Topics: Angiogenesis Inhibitors; Animals; Axitinib; Benzenesulfonates; Humans; Imidazoles; Indazoles; Indoles; Neoplasms; Neovascularization, Pathologic; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phthalazines; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptors, Fibroblast Growth Factor; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sulfonamides; Sunitinib

2012
[Nintedanib (BIBF 1120) in the treatment of solid cancers: an overview of biological and clinical aspects].
    Magyar onkologia, 2012, Volume: 56, Issue:3

    Topics: Animals; Antineoplastic Agents; Axitinib; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Colorectal Neoplasms; Digestive System; Enzyme Inhibitors; Female; Genital Neoplasms, Female; Humans; Imidazoles; Indazoles; Indoles; Liver Neoplasms; Lung Neoplasms; Male; Neoplasms; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phthalazines; Piperidines; Prostatic Neoplasms; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Quinazolines; Receptors, Fibroblast Growth Factor; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sulfonamides; Xenograft Model Antitumor Assays

2012
Inhibitors of the vascular endothelial growth factor receptor.
    Hematology/oncology clinics of North America, 2002, Volume: 16, Issue:5

    Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Clinical Trials as Topic; Colorectal Neoplasms; Drug Design; Drug Screening Assays, Antitumor; Endothelial Growth Factors; Enzyme Inhibitors; Humans; Indoles; Intercellular Signaling Peptides and Proteins; Lymphokines; Neoplasm Proteins; Neoplasms; Neovascularization, Pathologic; Phthalazines; Piperidines; Pyridines; Pyrroles; Quinazolines; Recombinant Proteins; RNA, Catalytic; Treatment Failure; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factors

2002
[Current screening for molecular target therapy of cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2003, Volume: 30, Issue:12

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzamides; Boronic Acids; Bortezomib; Drug Delivery Systems; Drug Screening Assays, Antitumor; Gefitinib; Heat-Shock Proteins; Humans; Imatinib Mesylate; Indoles; Lactones; Mice; Neoplasms; Phthalazines; Piperazines; Piperidines; Pyrazines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sunitinib

2003
Update on angiogenesis inhibitors.
    Current opinion in oncology, 2005, Volume: 17, Issue:6

    Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Colorectal Neoplasms; Humans; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phthalazines; Piperidines; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Signal Transduction; Sorafenib; Vascular Endothelial Growth Factor A

2005
[Problems in the current target therapy of malignancies].
    Voprosy onkologii, 2005, Volume: 51, Issue:5

    Topics: Alemtuzumab; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Azathioprine; Benzamides; Bevacizumab; Cetuximab; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Neoplasms; Phthalazines; Piperazines; Pyridines; Pyrimidines; Quinazolines; Quinolones; Rituximab; Sesquiterpenes; Sesquiterpenes, Guaiane; Trastuzumab

2005
Vatalanib: the clinical development of a tyrosine kinase inhibitor of angiogenesis in solid tumours.
    Expert opinion on investigational drugs, 2007, Volume: 16, Issue:3

    Topics: Angiogenesis Inhibitors; Animals; Clinical Trials as Topic; Humans; Neoplasms; Phthalazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines

2007
[Oral drugs inhibiting the VEGF pathway].
    Bulletin du cancer, 2007, Volume: 94 Spec No

    Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Asthenia; Axitinib; Benzenesulfonates; Humans; Hypertension; Imidazoles; Indazoles; Indoles; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phthalazines; Piperidines; Proteinuria; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A

2007

Trials

10 trial(s) available for vatalanib and Neoplasms

ArticleYear
A phase I study of the VEGFR kinase inhibitor vatalanib in combination with the mTOR inhibitor, everolimus, in patients with advanced solid tumors.
    Investigational new drugs, 2020, Volume: 38, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Everolimus; Female; Humans; Male; Middle Aged; Neoplasms; Phthalazines; Protein Kinase Inhibitors; Pyridines; Receptors, Vascular Endothelial Growth Factor; TOR Serine-Threonine Kinases; Treatment Outcome; Young Adult

2020
A phase I study of the vascular endothelial growth factor inhibitor Vatalanib in combination with Pemetrexed disodium in patients with advanced solid tumors.
    Investigational new drugs, 2019, Volume: 37, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pemetrexed; Phthalazines; Protein Kinase Inhibitors; Pyridines; Random Allocation; Treatment Outcome; Vascular Endothelial Growth Factor A

2019
A phase I trial of PTK787/ZK222584 in combination with pemetrexed and cisplatin in patients with advanced solid tumors.
    Investigational new drugs, 2009, Volume: 27, Issue:1

    Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Glutamates; Guanine; Humans; Male; Middle Aged; Neoplasms; Pemetrexed; Phthalazines; Pyridines

2009
A phase I dose escalation and pharmacokinetic study of vatalanib (PTK787/ZK 222584) in combination with paclitaxel in patients with advanced solid tumors.
    Cancer chemotherapy and pharmacology, 2010, Volume: 66, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Interactions; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Phthalazines; Pyridines; Transaminases; Treatment Outcome

2010
Phase 1 study of combination treatment with PTK 787/ZK 222584 and cetuximab for patients with advanced solid tumors: safety, pharmacokinetics, pharmacodynamics analysis.
    Neoplasia (New York, N.Y.), 2010, Volume: 12, Issue:2

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cell Separation; Cetuximab; Endothelial Cells; Female; Flow Cytometry; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Phthalazines; Pyridines; Stem Cells

2010
A phase IA, open-label, dose-escalating study of PTK787/ZK 222584 administered orally on a continuous dosing schedule in patients with advanced cancer.
    Anticancer research, 2010, Volume: 30, Issue:6

    Topics: Administration, Oral; Drug Administration Schedule; Female; Fibroblast Growth Factor 2; Humans; Magnetic Resonance Imaging; Male; Maximum Tolerated Dose; Neoplasms; Phthalazines; Protein Kinase Inhibitors; Pyridines; Vascular Endothelial Growth Factor A

2010
A phase I trial to determine the safety of imatinib in combination with vatalanib in patients with advanced malignancies.
    Cancer investigation, 2011, Volume: 29, Issue:4

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biopsy; Drug Administration Schedule; Female; Humans; Imatinib Mesylate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Phthalazines; Piperazines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Risk Assessment; Tennessee; Time Factors; Treatment Outcome; Young Adult

2011
A phase I trial of vatalanib (PTK/ZK) in combination with bevacizumab in patients with refractory and/or advanced malignancies.
    Clinical advances in hematology & oncology : H&O, 2011, Volume: 9, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Female; Humans; Male; Middle Aged; Neoplasm Staging; Neoplasms; Phthalazines; Protein Kinase Inhibitors; Pyridines; Receptors, Vascular Endothelial Growth Factor; Young Adult

2011
Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Jun-20, Volume: 23, Issue:18

    Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Area Under Curve; Chi-Square Distribution; Chromatography, High Pressure Liquid; Disease Progression; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasms; Phthalazines; Protein Kinase Inhibitors; Pyridines; Statistics, Nonparametric; Treatment Outcome

2005
Metabolism and disposition of vatalanib (PTK787/ZK-222584) in cancer patients.
    Drug metabolism and disposition: the biological fate of chemicals, 2006, Volume: 34, Issue:11

    Topics: Administration, Oral; Aged; Angiogenesis Inhibitors; Carbon Radioisotopes; Female; Humans; Male; Metabolic Detoxication, Phase I; Middle Aged; Molecular Structure; Neoplasms; Phthalazines; Pyridines; Tissue Distribution

2006

Other Studies

13 other study(ies) available for vatalanib and Neoplasms

ArticleYear
New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis.
    Journal of medicinal chemistry, 2000, Jun-15, Volume: 43, Issue:12

    Topics: Administration, Oral; Angiogenesis Inhibitors; Aniline Compounds; Animals; Biological Availability; Cell Line; CHO Cells; Cricetinae; Enzyme Inhibitors; Humans; Mice; Models, Molecular; Neoplasms; Neovascularization, Pathologic; Phosphorylation; Phthalazines; Proto-Oncogene Proteins; Pyridines; Receptor Protein-Tyrosine Kinases; Receptors, Growth Factor; Receptors, Vascular Endothelial Growth Factor; Structure-Activity Relationship; Transfection; Vascular Endothelial Growth Factor Receptor-1

2000
Pyridylmethylthio derivatives as VEGF inhibitors. Part 1.
    Bioorganic & medicinal chemistry letters, 2010, Dec-15, Volume: 20, Issue:24

    Topics: Anilides; Animals; Arthritis, Experimental; Cell Line; Choroidal Neovascularization; Disease Models, Animal; Endothelial Cells; Humans; Mice; Neoplasms; Pyridines; Rats; Structure-Activity Relationship; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays

2010
Pyridylmethylthio derivatives as VEGF inhibitors: part 2.
    Bioorganic & medicinal chemistry letters, 2011, Feb-15, Volume: 21, Issue:4

    Topics: Angiogenesis Inhibitors; Animals; Arthritis, Rheumatoid; Cells, Cultured; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Humans; Mice; Neoplasms; Neovascularization, Pathologic; Pyridines; Transplantation, Heterologous; Vascular Endothelial Growth Factor A

2011
Vascular endothelial growth factor (VEGF) receptors: drugs and new inhibitors.
    Journal of medicinal chemistry, 2012, Dec-27, Volume: 55, Issue:24

    Topics: Angiogenesis Inhibitors; Animals; Clinical Trials as Topic; Humans; Models, Molecular; Neoplasms; Pyridines; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Structure-Activity Relationship

2012
Differential effects of the vascular endothelial growth factor receptor inhibitor PTK787/ZK222584 on tumor angiogenesis and tumor lymphangiogenesis.
    Molecular cancer therapeutics, 2009, Volume: 8, Issue:1

    Topics: Animals; Antineoplastic Agents; Cell Proliferation; Disease Progression; Lymphangiogenesis; Mice; Mice, Inbred C57BL; Mice, Transgenic; Neoplasms; Neovascularization, Pathologic; Phthalazines; Protein Kinase Inhibitors; Pyridines; Receptors, Vascular Endothelial Growth Factor

2009
In-vivo visualization of tumor microvessel density and response to anti-angiogenic treatment by high resolution MRI in mice.
    PloS one, 2011, May-05, Volume: 6, Issue:5

    Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Humans; Magnetic Resonance Imaging; Mice; Microvessels; Neoplasms; Neovascularization, Pathologic; Phthalazines; Pyridines; Xenograft Model Antitumor Assays

2011
American Society of Clinical Oncology-39th Annual Meeting. Angiogenesis. 31 May-3 June 2003, Chicago, IL, USA.
    IDrugs : the investigational drugs journal, 2003, Volume: 6, Issue:7

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Clinical Trials as Topic; Humans; Neoplasms; Neovascularization, Pathologic; Oligopeptides; Phthalazines; Pyridines

2003
Protein kinase inhibitors: novel tools in cancer therapy.
    Der Urologe. Ausg. A, 2004, Volume: 43 Suppl 3

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Cell Transformation, Neoplastic; Gefitinib; Humans; Lung Neoplasms; Neoplasms; Phthalazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Quinazolines; Signal Transduction

2004
An image worth a thousand lives?
    Nature biotechnology, 2004, Volume: 22, Issue:6

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzoquinones; Bibenzyls; Diagnostic Imaging; Down-Regulation; ErbB Receptors; Gefitinib; Heterocyclic Compounds, 1-Ring; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Magnetic Resonance Imaging; Molecular Probe Techniques; Mutation; Neoplasms; Phthalazines; Physiological Phenomena; Positron-Emission Tomography; Protein Binding; Protein Kinase Inhibitors; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Receptors, Vascular Endothelial Growth Factor; Rifabutin; Stilbenes; Tissue Distribution; Trastuzumab

2004
A dual-color fluorescence imaging-based system for the dissection of antiangiogenic and chemotherapeutic activity of molecules.
    FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2004, Volume: 18, Issue:13

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Bibenzyls; Cell Line, Tumor; Coculture Techniques; Doxorubicin; Extracellular Matrix; Fluorescence; Hepatocyte Growth Factor; Humans; Melanoma; Neoplasms; Neovascularization, Pathologic; Phthalazines; Pyridines; Stilbenes; Thalidomide; Vascular Endothelial Growth Factor A

2004
The fight against cancer: the next round.
    Drug discovery today, 2004, Nov-15, Volume: 9, Issue:22

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Humans; Mice; Neoplasms; Neovascularization, Pathologic; Phthalazines; Pyridines; Receptors, Vascular Endothelial Growth Factor; Vascular Endothelial Growth Factor A

2004
PTK 787/ZK 222584, a tyrosine kinase inhibitor of all known VEGF receptors, represses tumor growth with high efficacy.
    Chembiochem : a European journal of chemical biology, 2005, Volume: 6, Issue:3

    Topics: Antineoplastic Agents; Cell Proliferation; Cells, Cultured; Endothelial Cells; Humans; Inhibitory Concentration 50; Molecular Structure; Neoplasms; Phosphorylation; Phthalazines; Protein Kinase Inhibitors; Pyridines; Receptors, Vascular Endothelial Growth Factor; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factor Receptor-3

2005
Targeted Therapies in Cancer - Fourth International Congress. Angiogenesis inhibition.
    IDrugs : the investigational drugs journal, 2005, Volume: 8, Issue:12

    Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Humans; Neoplasms; Neovascularization, Pathologic; Phthalazines; Pyridines; Quinazolines; Vascular Endothelial Growth Factor A

2005